In this Article, two papers are mistakenly listed as having made use of the antibody 14C8 instead of the antibody PPG5/10. In the Discussion section, ref. 45 is incorrectly cited as having shown that the antibody 14C8 works well, and in Fig. 5a, Saunders et al. 2000 is incorrectly depicted as using the 14C8 antibody. Both these papers used antibody PPG5/10 and neither paper includes experiments using 14C8. A corrected version of Fig. 5 appears below as Fig. 1.
Additional information
The online version of the original article can be found at https://doi.org/10.1038/ncomms15840
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Andersson, S., Sundberg, M., Pristovsek, N. et al. Correction: Corrigendum: Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun 8, 16164 (2017). https://doi.org/10.1038/ncomms16164
Published:
DOI: https://doi.org/10.1038/ncomms16164
This article is cited by
-
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors
Biomarker Research (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
